Implementación de protocolo perioperatorio para disminuir tasa de transfusiones en pacientes sometidos a reemplazo total de cadera o rodilla primarios

INTRODUCTION: Patient Blood Management (PBM) programs improve patient care and reduce health costs. It includes detection of presurgical anemia, reduction of blood loss and improvement of patient-specific anemic reserve. The aim of this study is to assess the effect of a PBM program on transfusion r...

Descripción completa

Detalles Bibliográficos
Autores principales: Godoy, Alejandro, Gonzalez, Jaqueline, Becerra, Ana Florencia, Finola, Mariano, Faule, Facundo, Estrada, Carlos, Neder, Yamile, Albertini, Ricardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Universidad Nacional de Córdoba 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741308/
https://www.ncbi.nlm.nih.gov/pubmed/34181839
http://dx.doi.org/10.31053/1853.0605.v78.n2.30134
Descripción
Sumario:INTRODUCTION: Patient Blood Management (PBM) programs improve patient care and reduce health costs. It includes detection of presurgical anemia, reduction of blood loss and improvement of patient-specific anemic reserve. The aim of this study is to assess the effect of a PBM program on transfusion rate, length of stay (LOS) and adverse events. METHODS: We developed a retrospective observational study. We included patients who underwent total hip (THR) o knee replacement (TKR). Our PBM involved preoperative assessment, administration of 2 doses of tranexamic acid, application of restrictive transfusion criteria and use of IV iron. We compared results between the group of patients before and the one after the PBM implementation. RESULTS: We included 179 patients (80 TKR and 99 THR) who underwent surgery before PBM implementation from January to December 2014 (Group A), and 187 patients (103 TKR and 84 THR) who underwent arthroplasty after PBM application from January to November 2016 (Group B). In Group A, hemoglobin drop was larger than in Group B, for TKR (5.1±1.2 vs. 4.2±1.2 g/dl; p<0,05) and for THR (4.7±1.3 vs. 3.8±1.3 g/dl; p<0,05). In group A, more patients were transfused (31.8% vs. 2.7%; p<0.001). LOS was longer for patients in group A, in both surgeries (for TKA, 3.98±1.4days vs. 2.99±0.95 days; p<0.0001; for THA 3.68±1.06days vs. 2.88±0.75days; p<0.0001). No significant differences were found regarding adverse events. CONCLUSION: Our PBM program saved transfusions after primary TKR and THR and lowered LOS, without risking patients to higher number of complications or death.